Long-term survival of patients with anaplastic thyroid cancer after multimodal treatment by 박정수 et al.
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2020;9(9):5430-5436 | http://dx.doi.org/10.21037/tcr-20-1364
Introduction
Anaplastic thyroid cancer (ATC) is extremely aggressive, 
with rapid disease progression, very short survival, and 
extremely poor treatment outcomes (1). In addition, 
although ATC is rare, accounting for only 1–2% of all 
thyroid cancers, deaths owing to ATC account for up to 
50% of all deaths caused by thyroid cancer (2,3). Moreover, 
the 1- and 10-year survival rates are 10–20% and less than 
5%, respectively, although the reliability of the diagnoses 
in these long-term survivors is debatable (4,5). Therefore, 
long-term survival is rare, having been reported in only a 
small number of selected patients.
The mechanisms of ATC progression are not completely 
understood. Surgery is the most effective treatment to 
improve prognosis; however, most cases cannot be managed 
because of the extent of local disease or distant metastasis 
at the time of initial diagnosis (6,7). Current chemotherapy 
regimens also have limited efficacy and have not resulted in 
a significant increase in overall survival (OS) (8). 
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ATC i s  current ly  t reated  wi th  chemotherapy, 
radiotherapy, targeted therapy, and/or surgery. Early 
mutations in BRAF and RAS have been reported in 25% 
and 28% of cases, respectively. BRAF V600E-positive 
malignancies were treated with the BRAF inhibitor 
dabrafenib (150 mg twice daily) plus the MEK inhibitor 
trametinib (2 mg once daily) (9). Other rare mutations and 
genetic aberrations, such as ALK translocations, may also 
be targeted via specific drugs (10). Because only less than 
30% of patients with ATC have genetic mutations that 
can be treated via targeted therapy, extended molecular 
profiling of ATC is strongly encouraged as it may reveal 
promising possibilities for targeted therapy. Accordingly, 
the use of targeted therapy, immunotherapy, chemotherapy 
and/or radiotherapy, in combination or in sequence, for 
multidisciplinary ATC management may improve patient 
outcomes (11).
The median OS of patients with ATC is 0.5 to 6 months 
worldwide, despite multimodal treatment (12,13); moreover, 
even after aggressive treatments, the median OS has not 
changed significantly in several decades (14). Accordingly, 
the current study aimed to describe our experience with the 
management of 23 patients with ATC who showed long-
term survival of more than 1 year and to determine the 
effective treatment that had an impact on the survival of 
more than 1 year.
We present the following article in accordance with the 




The medical records of 23 patients with pathologically 
proven ATC who survived for more than 1 year were 
retrospectively identified and reviewed from the single-
centre database system of the Gangnam Severance 
Hospital between January 2003 and December 2018. The 
management and outcome data of the 23 patients with a 
definitive histological diagnosis of ATC were reviewed 
(Figure 1). The American Joint Committee on Cancer 
(AJCC) staging system (8th edition) was used for tumour 
staging (15). The final pathologic confirmation was 
performed via surgery in 19 patients and via fine-needle 
aspiration biopsy in 4 patients. The histologic findings 
were examined by a pathologist to exclude the possibility 
of poorly differentiated carcinoma. The patient records 
were anonymised and de-identified prior to analysis, and 
hence, informed consent was not obtained from each 
participant. The study was approved by Institutional 
Review Board of Yonsei University (No. 3-2018-0135) and 
conducted in accordance with the Declaration of Helsinki 
(as revised in 2013). 
Surgery for ATC included radical resection for patients 
Patients with thyroid cancer from Gangnam 
Severance Database System
(n=31,234)
Patients with anaplastic thyroid cancer
(n=74)
6 patients were alive and 6 patients were dead
2 patients were alive and 3 patient were dead
Survival more than 1 year
(n=23)
Survival more than 2 years
(n=11)
Survival more than 3 years
(n=6)
Excluded (n=31,160)
1. Papillary, follicular, hurthle cell and poorly 
differentiated thyroid cancer
2. Loss of follow up
3. Insufficient medical record
Figure 1 Study population.
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with resectable tumours and partial/palliative resection 
for patients with unresectable tumours. Radical resection 
usually included total thyroidectomy because ATC 
commonly shows aggressive behaviour and extensive 
tumour burden at presentation (1). Partial thyroidectomy 
was performed when the patient had a low tumour burden 
and when the tumour was focally limited to one lobe of 
the thyroid. For patients with clinically positive cervical 
lymph nodes, level II to VI neck node dissection was also 
performed. When patients could not undergo surgery 
owing to poor general condition, old age, extensive tumour 
burden, or refusal to undergo surgery, tracheostomy and 
tumour biopsy were performed.
Among chemotherapeutic regimens, paclitaxel-based 
concurrent chemoradiotherapy (CCRT) was usually 
administered before and after surgery in our institution 
according to the clinicians’ preference and patients’ 
condition. If patients could not tolerate CCRT, physicians 
occasionally decided to administer RT only. Sequential 
chemotherapy with paclitaxel after CCRT was also 
administered if necessary.
Thyrosine kinase inhibitor, LENVIMA®[lenvatinib] was 
administered according to ATC Yonsei university medical 
center (YUMC) protocol. We administered lenvatinib 
10 mg a day, to patients who had progression after 
underwent surgery and 3 cycles of adjuvant paclitaxel mono 
chemotherapy.
If unresectable and no progression, the patient underwent 
4 cycles of adjuvant paclitaxel mono chemotherapy and 
external radiation therapy. And then the cancer was 
progression, we add lenvatinib 10 mg a day. If unresectable 
and progression, the patient underwent 4 cycles of adjuvant 
paclitaxel mono chemotherapy and external radiation 
therapy and lenvatinib is orally administered 10 mg a day. If 
more progression, we add lenvatinib 10 mg a day.
Statistical analysis
OS was defined as the time from the date of the first 
treatment to the time of death owing to any cause or last 
follow-up. Survival rates were calculated using the Kaplan-
Meier method. All these analyses were performed with the 
statistical program package SPSS for windows, version 22. 
Results
Clinical and pathological characteristics
The demographic data of the 23 included patients are 
presented in Tables 1,2. Among the 23 patients, 11 were men 
and 12 were women, with a median age of 58.3 years (range, 
27–78 years). A total of 19 patients (82.6%) had symptoms. 
Thirteen patients (68.4%) had a palpable mass, 4 (21.1%) 
had localised pain, and 2 (10.5%) had dyspnoea. Overall, 9 
patients (39.1%) had distant metastasis (Table 2).
The Eastern Cooperative Oncology Group (ECOG) 
performance status score was 0 in 14 patients (78.3%), 1 in 
4 patients (17.4%), and 2 in 1 patient (4.3%). At the time 
of diagnosis, 14 patients (60.9%) had stage IVB disease and 
9 patients (39.1%) had stage IVC disease according to the 
AJCC 8th edition (Table 2).
Treatment characteristics are shown in Table 3. In total, 
14 patients were treated with a combination of surgery and 
radiotherapy with or without chemotherapy. Only 5 patients 
were treated with surgery alone. Overall, 15 patients 
underwent R0 resection, 2 underwent R1 resection, and 2 
underwent R2 resection.
Survival rates
The median survival of patients was 1,090 days. The median 
follow-up was 646 days. The 2- and 3-year survival rates 
were 59.7% and 35.8%, respectively (Figure 2). Overall, 
10 patients died: 7 owing to local disease and 3 owing to 
distant metastasis (Table 4).
Discussion
ATC is more common in women than in men. On 
evaluating the data of patients in the Surveillance, 
Epidemiology, and End Results database from 1973 to 
2014, a total of 1,527 patients were diagnosed with ATC in 
the SEER 18 registries (16). Of 1,527 patients, 959 (62.8%) 
were women and 568 (37.2%) were men; the mean age 
was 70.5 years (16). However, in the current study, there 
were no differences considering the patient sex, and only 4 
patients were older than 70 years; the median age was only 
58.3 years (range, 27–78 years).
The ECOG performance status score was 0 in 14 
patients (78.3%), 1 in 4 patients (17.4%), and 2 in 1 patient 
(4.3%). In fact, a lower ECOG performance status score 
is associated with better treatment tolerance and smooth 
recovery.
The locoregional invasiveness of ATC may cause 
compressive symptoms such as dysphagia, dyspnoea, stridor, 
and pain. In the current study, 19 patients (82.6%) had 
symptoms on diagnosis. This was similar to the result of a 
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retrospective study in which the majority of patients (86.1%) 
presented with compressive symptoms (17). Therefore, the 
presence of compressive symptoms does not affect OS nor 
does it result in early diagnosis despite aggressive disease 
progression. In fact, in the current study, all the patients 
who did not undergo R0 resection or surgery were treated 
with radiotherapy, which reduced local recurrence, thereby 
resulting in longer OS.
More than 60% of patients with ATC present with 
distant metastasis (18). In the current study, only 9 patients 
(39.1%) had distant metastasis. All the 9 patients had distant 
metastasis to the lungs, and they also had bone, brain, and 
adrenal metastasis. When patients with ATC do not have 
distant metastasis, the possibility of performing surgery is 
higher; therefore, there is no evidence that indicates that 
distant metastasis increased the OS and complete remission 
rate. 
In the current study, 82.6% of the patients underwent 
surgery and received multimodal therapy. A total of 15 
patients underwent R0 resection, 2 underwent R1 resection, 
and 2 underwent R2 resection. Early maximal debulking 
surgery or R0 resection and systemic chemotherapy 
and radiotherapy may influence the survival of patients 
(12,18,19). However, the benefit of aggressive surgery 
is often of limited clinical significance in advanced cases 
and is possibly outweighed by the associated morbidity. 
Table 1 Patient characteristic
Patient Sex Age (y) Stage Surgery CTx administered RTx dose TKI administered Survival status Survival days
1 Female 75 4c R0 No NA No Dead 646
2 Male 47 4b R0 No NA No Alive 3,525
3 Female 67 4c R0 No 5,580 No Dead 1,090
4 Female 37 4b R0 No NA No Alive 3,058
5 Female 61 4b R0 No 6,600 No Alive 1,553
6 Male 66 4b No Yes 7,800 Yes Dead 506
7 Female 79 4b R1 No NA No Dead 483
8 Female 69 4c R0 Yes 7,412 Yes Dead 633
9 Female 72 4b No Yes 3,360 Yes Dead 1,316
10 Male 59 4c R0 No 3,500 Yes Dead 913
11 Female 55 4b R0 Yes 4,400 No Alive 1,340
12 Female 51 4b R0 No NA No Alive 1,205
13 Male 74 4b R1 Yes 6,510 No Alive 831
14 Male 67 4c No Yes 6,000 No Dead 546
15 Female 64 4c R1 Yes 7,880 No Alive 630
16 Male 59 4c No Yes 5,400 No Dead 410
17 Male 60 4c R0 Yes 6,000 Yes Dead 839
18 Male 56 4b R0 Yes 5,880 No Alive 742
19 Male 28 4b R0 Yes 6,000 No Alive 631
20 Female 64 4c R2 Yes 3,080 Yes Alive 390
21 Male 42 4b R0 Yes 6,000 No Alive 422
22 Female 53 4b R0 Yes 4,000 No Alive 419
23 Male 41 4b R2 Yes 4,000 No Alive 376
CTx, chemotherapy; RTx, radiotherapy; TKI, tyrosine kinase inhibitor; NA, not administered.
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Moreover, negative margins may not have any survival 
benefit (20). In fact, surgery alone may not have any survival 
benefit. However, R0 resection combined with multimodal 
therapy increased OS. The 2- and 3-year survival rates were 
59.7% and 35.8%, respectively, indicating the possibility 
of complete remission in patients with ATC. In fact, the 
possibility of complete remission is higher in patients who 
survive for more than 1 year than in other patients. In our 
treatment centre, we have administered the ATC YUMC 
protocol (Figure 3) for patients with ATC since 2015, which 
is why it is difficult to compare the results obtained for 
our patients to those obtained for other patients because 
of the use of a unified treatment protocol. Therefore, in 
the future, a comparison study is required for evaluating 
patients with ATC before and after the use of the ATC 
YUMC protocol.




Age (years), mean ± SD, (range) 58.5±13.0 [27–78] 
Male:female ratio 11:12 (47.8:52.2) 
Clinical presentation 19 (82.6) 
Palpable mass 13 (68.4) 
Hoarseness 1 (5.3) 
Localized pain 4 (21.1) 
Dyspnoea 2 (10.5) 
Dysphagia 1 (5.3) 
Motor nerve palsy 1 (5.3) 
Every weight loss 1 (5.3) 
Eastern Cooperative Oncology 
Group performance status score 
0:1:2 ratio 14 (78.3):4 (17.4):1 (4.3) 
Distant metastasis 9 (39.1) 
Lungs 9 (100.0) 
Bone 2 (22.2) 
Brain 2 (22.2) 
Adrenal gland 1 (11.1) 
Stage at diagnosis 
IVB:IVC 14 (60.9):9 (39.1) 
Data are given as n (%) unless indicated otherwise.
Table 3 Treatment characteristics
Variables n (%)
Treatment modality 
Surgery + RTx + CTx + TKI 3 (13.0) 
Surgery + RTx + CTx 8 (34.8) 
Surgery + RTx + TKI 1 (4.3) 
Surgery + RTx 2 (8.7) 
Surgery only 5 (21.7) 
RT + CTx + TKI 2 (8.7) 
RT + CTx 2 (8.7) 
Surgery 19 (82.6) 
R0 resection 15 (78.9) 
R1 resection 2 (10.5) 
R2 resection 2 (10.5) 
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Figure 2 Kaplan-Meier survival analysis of overall survival for all 
23 patients with anaplastic thyroid carcinoma.
Table 4 Survival rate and mortality
Variables 
Median follow-up, days 646 [376–3,525] 
Median survival, days 1,090 [376–3,525] 
2-year survival rate (%) 59.7 
3-year survival rate (%) 35.8 
Number of patients who died 10 (43.5) 
Cause of death
Local disease 3 (30.0)
Distant metastasis 7 (70.0) 
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This study had several limitations. This was an 
observational study, and the results were dependent on the 
completeness and accuracy of the medical records used. In 
addition, as this study only included patients from a single 
centre, the generalizability of the current findings may be 
limited. Moreover, in case of cancers with a high mortality 
such as pancreatic cancer, it is preferable to review the long-
term survival of patients. Nevertheless, as the current study 
aimed to identify the characteristics of patients with ATC 
who survived for more than 1 year, the results could be the 
basis for further research. Furthermore, the findings of 
this study will help in increasing the rate of treatment for 
patients with ATC.
Conclusions
In conclusion, Although ATC is typically an incurable 
disease, patients with ATC who underwent multimodality 
treatments including resection, chemotherapy, radiotherapy, 
and thyrosine kinase inhibitors may be survive more than 
1 year.
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If progression, lenvatinib add 
4 cycles of paclitaxel 70 mg/m2
External radiation therapy 2640 cGy
Figure 3 Anaplastic thyroid cancer Yonsei university medical center protocol.
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